Bio Path Holdings Inc

NASDAQ:BPTHUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.

Contact Information

Headquarters

4710 BELLAIRE BOULEVARD, SUITE 210BELLAIRE, TX, United States 77401

Phone

832-742-1357

Fax

916-443-1908

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Treasurer

Peter Nielsen

Director of Investor Relations, Secretary, Director

Douglas Morris

Independent Director

Paul Aubert

Independent Director

Heath Cleaver

Independent Director

Aline Sherwood